FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients.

被引：0
|
作者：
Neuzillet, C.
Hentic, O.
Rousseau, B.
Rebours, V.
Bengrine-Lefevre, L.
Bonnetain, F.
Raymond, E.
Ruszniewski, P.
Louvet, C.
Hammel, P.
机构：
[1] Hop Beaujon, Clichy La Garenne, France
[2] Hop St Antoine, F-75571 Paris, France
[3] Ctr Georges Francois Leclerc, Dijon, France
[4] Beaujon Univ Hosp, Clichy, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4132
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study
    Zhao, Jie
    Guo, Yongzhong
    Feng, Tianshuo
    Rong, Dawei
    Kong, Xiangyi
    Huang, Tian
    Lopez-Lopez, Victor
    Yarmohammadi, Hooman
    Sakamoto, Yoshihiro
    Zhu, Deming
    Yao, Aihua
    Xia, Yongxiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2549 - 2558
  • [42] A multi-center retrospective analysis of patients with relapsed/refractory follicular lymphoma after third-line chemotherapy
    Shigeo Fuji
    Yuma Tada
    Kenji Nozaki
    Hideaki Saito
    Takayuki Ozawa
    Toru Kida
    Satoru Kosugi
    Hiroyuki Sugahara
    Hirokazu Ikeda
    Koji Hashimoto
    Takahiro Karasuno
    Shuji Ueda
    Jun Ishikawa
    Hirohiko Shibayama
    Annals of Hematology, 2020, 99 : 2133 - 2139
  • [43] Comparison of the effectiveness of liposomal doxorubicin and gemcitabine in patients with platinum-sensitive recurrent ovarian cancer receiving third-line chemotherapy
    Bayram, E.
    Khatib, G.
    Kucukgoz-Gulec, U.
    Guzel, A. B.
    Vardar, M. A.
    Paydas, S.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (14) : 6618 - 6626
  • [44] Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Tschoep-Lechner, Katharina Elisabeth
    Milani, Valeria
    Berger, Frank
    Dieterle, Nelli
    Abdel-Rahman, Sultan
    Salat, Christoph
    Issels, Rolf-Dieter
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2013, 29 (01) : 8 - 16
  • [45] GEMCITABINE AND CISPLATIN COMBINED WITH REGIONAL HYPERTHERMIA AS SECOND-LINE TREATMENT IN PATIENTS WITH GEMCITABINE-REFRACTORY ADVANCED PANCREATIC CANCER
    Lechner, Katharina
    Berger, Frank
    Dieterle, Nelli
    Abdel-Rahman, Sultan
    Salat, Christoph
    Issels, Rolf
    ANNALS OF ONCOLOGY, 2012, 23 : 62 - 62
  • [46] A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer
    Goncalves, A.
    Fabbro, M.
    Lhomme, C.
    Gladieff, L.
    Extra, J. -M.
    Floquet, A.
    Chaigneau, L.
    Carrasco, A. Tisseron
    Viens, P.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (01) : 42 - 46
  • [47] Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
    Bukhari, Nedal
    Abdalla, Khalda
    Ibnshamsa, Fahad
    Alselwi, Waleed
    Al-Shakir, Shakir
    Alqahtani, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [48] Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
    Leleu, X.
    Kyriakou, C.
    Broek, Vande
    Murphy, P.
    Bacon, P.
    Lewis, P.
    Gilet, H.
    Arnould, B.
    Petrucci, M. T.
    BLOOD CANCER JOURNAL, 2017, 7 : e543 - e543
  • [49] Optimal Second Line Treatment Options for Gemcitabine Refractory Advanced Pancreatic Cancer Patients. Can We Establish Standard of Care with Available Data?
    Kang, Soonmo Peter
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2008, 9 (02): : 83 - 90
  • [50] Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
    X Leleu
    C Kyriakou
    I Vande Broek
    P Murphy
    P Bacon
    P Lewis
    H Gilet
    B Arnould
    M T Petrucci
    Blood Cancer Journal, 2017, 7 : e543 - e543
12345